Aceto boosts biomanufacturing footprint with acquisition of Ireland-based A&C Bio Buffer
The transaction expands the CDMO's GMP biopharmaceutical and vaccine manufacturing capabilities
After acquiring excipients specialist A&C in April this year, Aceto has now struck a deal to acquire Ireland-based A&C Bio Buffer, a GMP manufacturer of custom buffer and chemical blend products used to manufacture biopharmaceutical drug products.
The transaction, described by the CDMO's CEO Gilles Cottier as a "natural add-on", compliments the company's expanded business development efforts in the biopharmaceutical sector.
According to Cottier, A&C Bio Buffer played a key role in the raw material supply chain for COVID-19 vaccines, and serves some of the leading biopharmaceutcial companies in Europe.
Located in Limerick, Ireland, A&C Bio Buffer produces more than 50 products including biological buffers, process solutions, cleaning solutions and water for injection (WFI) for companies operating in Ireland and Europe.
This is the sixth company with expanded manufacturing, R&D and portfolio offerings that Aceto has acquired during the last 2 years, giving it a robust manufacturing footprint. The company now has business operations in 10 countries, manufacturing and supplying more than 3,000 chemical compounds.
Click here for an interview with Aceto CEO, Gilles Cottier about the company's strategy and future.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...